Zobrazeno 1 - 10
of 45
pro vyhledávání: '"Doncho V Zhelev"'
Autor:
Paul M Sondel, Amy K Erbe, Daniel Martinez, Samantha N Buongervino, Kristopher R Bosse, Guillem Pascual-Pasto, Brendan McIntyre, Rawan Shraim, Doncho V Zhelev, Shakhnozakhon Sadirova, Anna M Giudice, Laura Garcia-Gerique, Dimiter S Dimitrov
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 12 (2022)
Background Antibody–drug conjugates (ADCs) that deliver cytotoxic drugs to tumor cells have emerged as an effective and safe anticancer therapy. ADCs may induce immunogenic cell death (ICD) to promote additional endogenous antitumor immune response
Externí odkaz:
https://doaj.org/article/01e319d8e2634ac2869c9e31926d7548
Publikováno v:
Frontiers in Oncology. 13
Chimeric antigen receptor-T (CAR-T) cells and antibody-drug conjugates (ADCs) are promising therapeutic strategies in oncology. The carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) is overexpressed in tumors including non-small cel
Autor:
Samantha Buongervino, Kristopher R. Bosse, Doncho V. Zhelev, Maria Lane, Dimiter S. Dimitrov, Emily Garrigan
Publikováno v:
Mol Cancer Ther
Antibody–drug conjugates (ADC) are a targeted cancer therapy that utilize the specificity of antibodies to deliver potent drugs selectively to tumors. Here we define the complex interaction among factors that dictate ADC efficacy in neuroblastoma b
Autor:
Guillem Pascual-Pasto, Brendan McIntyre, Rawan Shraim, Samantha N Buongervino, Amy K Erbe, Doncho V Zhelev, Shakhnozakhon Sadirova, Anna M Giudice, Daniel Martinez, Laura Garcia-Gerique, Dimiter S Dimitrov, Paul M Sondel, Kristopher R Bosse
Publikováno v:
Journal for ImmunoTherapy of Cancer. 10:e004704
BackgroundAntibody–drug conjugates (ADCs) that deliver cytotoxic drugs to tumor cells have emerged as an effective and safe anticancer therapy. ADCs may induce immunogenic cell death (ICD) to promote additional endogenous antitumor immune responses
Autor:
Chien-Te K Tseng, Swarali S. Kulkarni, Dimiter S. Dimitrov, Ralph S. Baric, Aleksandra Drelich, Wei Li, Alex Conard, Xianglei Liu, David R. Martinez, Sarah R. Leist, Chuan Chen, Doncho V. Zhelev, Darryl Falzarano, John W. Mellors, Zehua Sun, Lisa E. Gralinski, Eric C. Peterson, Alexandra Schäfer, Ye-Jin Kim, Liyong Zhang
Publikováno v:
Proceedings of the National Academy of Sciences of the United States of America
Proceedings of the National Academy of Sciences
Proceedings of the National Academy of Sciences
Significance Effective therapies are urgently needed for COVID-19. We rapidly (within a week) identified a fully human monoclonal germline-like antibody (ab1) from phage-displayed libraries that potently inhibited mouse ACE2-adapted SARS-CoV-2 replic
Autor:
Yimei Li, John M. Maris, Swetha Raman, Jean-Philippe Julien, Bruce R. Pawel, Maria Lane, Dimiter S. Dimitrov, Kristen A. Upton, Kristopher R. Bosse, Daniel B. Harmon, Carmen T. Navia, Doncho V. Zhelev, Hong Cui, Khushbu Patel, Samantha Buongervino, Yanping Wang, Komal S. Rathi, Zhongyu Zhu, Daniel Martinez, Benjamin Martinez
Publikováno v:
Cell Reports Medicine
Summary Glypican 2 (GPC2) is a MYCN-regulated, differentially expressed cell-surface oncoprotein and target for immune-based therapies in neuroblastoma. Here, we build on GPC2’s immunotherapeutic attributes by finding that it is also a highly expre
Autor:
Leist, David R. Martinez, Dimiter S. Dimitrov, Lisa E. Gralinski, John W. Mellors, Liyong Zhang, Eric C. Peterson, Aleksandra Drelich, Zhuoxin Sun, Chien-Te Tseng, Xianglei Liu, Wei Li, Ralph S. Baric, Alexandra Schäfer, Chuan Chen, Doncho V. Zhelev, Alex Conard
Effective therapies are urgently needed for the SARS-CoV-2/COVID19 pandemic. We identified panels of fully human monoclonal antibodies (mAbs) from eight large phage-displayed Fab, scFv and VH libraries by panning against the receptor binding domain (
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b165f8b163681bb25e97877a0e7beef5
https://doi.org/10.1101/2020.05.13.093088
https://doi.org/10.1101/2020.05.13.093088
Autor:
Khushbu Patel, Hong Cui, Kristen A. Upton, Kristopher R. Bosse, Carmen T. Navia, Doncho V. Zhelev, Daniel Martinez, Daniel B. Harmon, Jean-Philippe Julien, John M. Maris, Benjamin Martinez, Bruce R. Pawel, Swetha Raman, Yanping Wang, Maria Lane, Dimiter S. Dimitrov, Samantha Buongervino, Komal S. Rathi, Zhongyu Zhu
Publikováno v:
SSRN Electronic Journal.
The signaling co-receptor heparan sulfate proteoglycan GPC2 is a MYCN-activated, differentially-expressed cell surface oncoprotein and candidate immunotherapeutic target in neuroblastoma. Here we build on GPC2’s attributes as a robust target for im
Autor:
Young K. Song, Dimiter S. Dimitrov, Robert Hawley, Ronald Sams, Javed Khan, Zhongyu Zhu, Dina Schneider, Adam Cheuk, Joon-Yong Chung, Meijie Tan, Doncho V. Zhelev, Stephen M. Hewitt, Marielle E. Yohe, Ben Stanton, Boro Dropulic, Jun S. Wei, Silvia Pomella, Rossella Rota, Sivasish Sindiri, Berkley E. Gryder, Xinyu Wen, Jeetendra Kumar, Peter Azorsa, Rimas J. Orentas, Nityashree Shivaprasad
Publikováno v:
Cancer Research. 80:A08-A08
Background: Despite decades of multimodule therapies, RMS remains incurable once it has metastasized; thus, new therapeutic strategies are warranted. FGFR4 is a developmentally regulated cell surface receptor tyrosine kinase, overexpressed in virtual
Autor:
Swetha Raman, John M. Maris, Samantha Buongervino, Daniel Martinez, Maria Lane, Dimiter S. Dimitrov, Jean-Philippe Julien, Kristopher R. Bosse, Doncho V. Zhelev, Hong Cui, Benjamin Martinez, Kristen A. Upton, Bruce R. Pawel
Publikováno v:
Cancer Research. 80:A26-A26
Introduction: We previously identified glypican 2 (GPC2) as a MYCN-driven neuroblastoma oncoprotein that is robustly differentially expressed, including expression of a tumor specific isoform (Cancer Cell 2017). We exploited this differential express